Magnolia Medical Technologies, Inc. v. Kurin, Inc.

CourtDistrict Court, D. Delaware
DecidedMay 20, 2020
Docket1:19-cv-00097
StatusUnknown

This text of Magnolia Medical Technologies, Inc. v. Kurin, Inc. (Magnolia Medical Technologies, Inc. v. Kurin, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Magnolia Medical Technologies, Inc. v. Kurin, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MAGNOLIA MEDICAL TECHNOLOGIES, INC., Plaintiff, Civil Action No. 19-97-CFC-CJB Vv. KURIN, INC., Defendant.

Douglas E. McCann and Robert M. Oakes, FISH & RICHARDSON P.C., Wilmington, Delaware; Mathias W. Samuel, FISH & RICHARDSON PC., Minneapolis, Minnesota; Corrin N. Drakulich, FISH & RICHARDSON PC., Atlanta, Georgia; Juanita R. Brooks, FISH & RICHARDSON PC., San Diego, California Counsel for Plaintiff Kenneth L. Dorsney, MORRIS JAMES LLP, Wilmington, Delaware; Karen I. Boyd, Louis Wai and Jacob Zweig, TURNER BOYD LLP, Redwood City, California; Jonathan Hangartner, X-PATENTS, APC, La Jolla, California Counsel for Defendant

MEMORANDUM OPINION

May 20, 2020 Wilmington, Delaware

(Phan AL COLM F. CONNOLLY UNITED STATES DISTRICT JUDGE Plaintiff Magnolia Medical Technologies, Inc. has sued Defendant Kurin, Inc. for infringing four patents that teach apparatus, methods, and/or systems related to the collection of bodily fluids for laboratory analysis. I held a claim construction hearing on April 15, 2020 and made a number of oral rulings. Two claim construction issues remain in dispute. A. “Diverter” The first issue concerns the term “diverter” in claims 1 and 21 of U.S. Patent No. 9,855,001 (the #001 patent). Claim 1 reads as follows: An apparatus for obtaining a bodily fluid sample from a patient with reduced contamination, the apparatus comprising: a reservoir configured to receive an initial volume of bodily fluid withdrawn from the patient; and.

a diverter having an inlet, a first outlet in fluid communication with the reservoir, and a second outlet, the inlet configured to be fluidically coupled to the patient, the diverter operable in a first operating mode in which an initial volume of bodily fluid can flow from the inlet to the first outlet, and a second operating mode in which: a) a subsequent volume of bodily fluid can flow from the inlet to the second outlet, and b) the initial volume of bodily fluid is prevented from flowing to the second outlet,

the diverter configured to transition from the first operating mode to the second operating mode as a result of the initial volume of bodily fluid flowing from the patient and _ substantial pressure equalization, thereby sequestering in the reservoir contaminants present in the initial volume of bodily fluid, thereby reducing contamination of the subsequent volume of bodily fluid withdrawn from the patient. #001 patent at 11:8—32 (emphasis added). Claim 21 teaches a similar apparatus that has

a diverter fluidically coupled to the needle, the diverter including an inlet, an outlet, and a reservoir configured to receive an initial volume of bodily fluid withdrawn from the patient, the diverter defining a first fluid flow path that allows the initial volume of bodily fluid to flow from the patient until pressure substantially equalizes, and a second fluid flow path that allows a subsequent volume of bodily fluid to flow from the inlet to the outlet after the initial volume of bodily fluid has been sequestered, the diverter configured to divert the flow of bodily fluid to the second fluid flow path as a result of receiving the initial volume of bodily fluid from the patient and substantial pressure equalization.... Id. at 13:11-23 (emphasis added). Claim 28, which recites another apparatus with

a diverter, depends from claim 21. Kurin argues that I should construe all the asserted claims that require a “diverter” as “means-plus function” claims under 35 U.S.C. § 112, | 6,' because

' Paragraph 6 of 35 U.S.C. § 112 was replaced by § 112(f) when the America Invents Act (AIA), Pub.L. No. 112-29, 125 Stat. 284 (2011) took effect on September 16, 2012. Because the provisional application resulting in the #001

the asserted claim limitations describe “diverter” in functional language without reciting sufficient structure to perform the described function. D.I. 59 at 45-46. Magnolia argues that construction of “diverter” is not necessary because its plain and ordinary meaning is apparent. Alternatively, Magnolia asks me to construe the term to mean “a component with an inlet and two outlet branches for directing the flow of fluid.” Jd. at 40. 1. Legal Standards Under § 112, | 6 of the Patent Act, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof... .”? The privilege afforded by § 112, | 6 to claim an element as a means to perform a function comes with a price, because the statute requires that functional claims “shall be construed to cover the corresponding structure, material, or acts described in the specification or equivalents thereof.” This requirement effectively imports

patent was filed before that date, I refer to the pre-AIA version of § 112. 2 Although § 112, { 6 literally applies only to a claimed “combination,” all inventions are effectively combinations, as “invention itself is the process of combining prior art in a nonobvious manner.” Jn re Rouffet, 149 F.3d 1350, 1359 (Fed. Cir. 1998); see also Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1540 (Fed. Cir. 1983) (“Reference to ‘combination’ patents is . .. meaningless. Virtually all patents are ‘combination patents,’ if by that label one intends to describe patents having claims to inventions formed of a combination of elements. It is difficult to visualize, at least in the mechanical-structural arts, a ‘non- combination’ invention, i.e., an invention consisting of a single element. Such inventions, if they exist, are rare indeed.”).

into a claim covered by § 112, § 6 structural limitations from elsewhere in the specification. Thus, patentees who choose to claim their invention in “means-plus- function” language limit the scope of their invention to the structure disclosed in the specification that performs the claimed function. See Williamson v. Citrix Online, LLC, 792 F.3d 1339, 1347 (Fed. Cir. 2015) (en banc) (“In enacting [§ 112, { 6], Congress struck a balance in allowing patentees to express a claim limitation by reciting a function to be performed rather than by reciting structure for performing that function, while placing specific constraints on how such a limitation is to be construed, namely, by restricting the scope of coverage to only the structure, materials, or acts described in the specification as corresponding to the claimed function and equivalents thereof.”). Federal Circuit precedent “has long recognized the importance of the

presence or absence of the word ‘means’” when determining whether § 112, 4 6 applies to a claim limitation. /d. If “means” is used in the limitation in question, then there is a rebuttable presumption that § 112, 6 applies; if “means” is not used in the limitation, then there is a rebuttable presumption that § 112, ] 6 does not apply. Jd. at 1348. In Williamson, however, the Federal Circuit expressly rejected the notion that these presumptions are “strong” and it admonished district courts not to “blindly elevate[] form over substance when evaluating whether a claim limitation

invokes § 112, para. 6.” Jd.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Magnolia Medical Technologies, Inc. v. Kurin, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/magnolia-medical-technologies-inc-v-kurin-inc-ded-2020.